Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON
  1. Home
  2. Azioni
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. SocietÓ
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
Prezzo di chiusura. Prezzo di chiusura Hong Kong Stock Exchange - 24/09
117.8 HKD   -2.24%
RiassuntoGraficiRatingAgendaSocietÓFinanzaConsensusRevisioni 
AttivitÓ
WUXI BIOLOGICS (CAYMAN) INC. Ŕ una holding di investimento. La SocietÓ, insieme alle sue controllate, Ŕ impegnata principalmente nella scoperta, ricerca e sviluppo, produzione e vendita di prodotti biologici. I prodotti primari della societÓ comprendono i principi attivi farmaceutici clinici, preparati liquidi sterili, preparati liofilizzati, nonchÚ piccole molecole di antibiotici per farmaci iniettabili. La SocietÓ distribuisce i propri prodotti principalmente nei mercati degli Stati Uniti d'America (USA) e della Repubblica Popolare Cinese (RPC).

Numero di dipendenti : 6 646 persone.
Vendite per attivitÓ
20192020Delta
Biologics Services4 517.17100%6 306.60100% +39.61%
HKD in Milioni
Vendite per regione
20192020Delta
North America2 423.7653.7%2 785.8144.2% +14.94%
China1 596.1235.3%2 768.9143.9% +73.48%
Europe353.177.8%501.858% +42.1%
Rest of the World144.123.2%250.034% +73.49%
HKD in Milioni
Dirigenti
Nome Titolo EtÓ Da
Zhi Sheng Chen Chief Executive Officer & Executive Director 47 2016
Shao Hua Lu-Wong Co-Chief Financial Officer 51 2021
Ming Tu Co-Chief Financial Officer & Executive VP 52 2021
Weichang Zhou Executive Director, Chief Technology Officer & EVP 57 2019
William Robert Keller Independent Non-Executive Director 72 2017
Teh Ming Kwauk Independent Non-Executive Director 67 2017
Kenneth Walton Hitchner Independent Non-Executive Director 59 2020
Pik Yuk Cheng Joint Secretary 62 2017
Yue Huang Co-Secretary - 2018
Chiang Syin, Dr. Chief Quality Officer 66 2018
Amministratori
Nome Titolo EtÓ Da
Ge Li, Dr. Non-Executive Chairman 54 2014
Zhi Sheng Chen Chief Executive Officer & Executive Director 47 2016
Ning Zhao, Dr. Non-Executive Director 54 2021
Weichang Zhou Executive Director, Chief Technology Officer & EVP 57 2019
Yan Ling Cao Non-Executive Director 36 2016
William Robert Keller Independent Non-Executive Director 72 2017
Teh Ming Kwauk Independent Non-Executive Director 67 2017
Kenneth Walton Hitchner Independent Non-Executive Director 59 2020
Yi Bing Wu, Dr. Non-Executive Director 52 2016
Azioni
Voto QuantitÓFlottanteAutocontrolloFlottante totale
Azione A 1 4 240 091 678 3 576 324 688 84.3% 0 0.0% 84.3%
Azionisti
NomeAzioni%
Wuxi Biologics Holdings Ltd. 650 251 133 15,3%
Capital Research & Management Co. (World Investors) 285 968 952 6,74%
The Vanguard Group, Inc. 102 313 592 2,41%
JPMorgan Investment Management, Inc. 96 589 000 2,28%
BlackRock Fund Advisors 72 300 000 1,71%
JPMorgan Asset Management (Asia Pacific) Ltd. 68 238 000 1,61%
Invesco Advisers, Inc. 63 279 020 1,49%
Capital Research & Management Co. (Global Investors) 51 923 105 1,22%
Jennison Associates LLC 51 760 666 1,22%
WCM Investment Management LLC 49 361 876 1,16%
Partecipazioni
NomeAzioni%Valorizzazione
I-MAB 1 156 110 0,67% 35 641 623 USD
MORIMATSU INTERNATIONAL HOLDINGS COMPANY LIMITED (2155) 18 856 000 1,82% 27 154 148 USD
Coordinate societÓ
Wuxi Biologics (Cayman), Inc.
No. 108, Meiliang Road
Mashan
Wuxi, Jiangsu 214092

Phone : +86.510.81831205
Web : http://www.wuxibiologics.com
Portafoglio di marchi
In collaborazione conAllbrands.markets
Pi¨ marchi di WuXi Biologics (Cayman) Inc.